Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02511106 · OUTCOME

Overall Survival (OS)

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. · Source last updated 2026-03-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Months
Interval / dispersion
95% Confidence Interval
Time frame
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)

What was measured

Defined as the time from the date of randomization until date of death due to any cause.

Analysis population: Full Analysis Set (FAS) stage IIA-IIIA patients

Groups in this outcome

AZD9291 80mg Tablet

Taken once daily

Placebo Tablet

Taken once daily

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
AZD9291 80mg Tablet233
Placebo Tablet237

Reported measurements

Source class 1
Values in Months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
AZD9291 80mg TabletNANot reportedNANAInsufficient OS events to estimate median and 95% confidence interval (Kaplan Meier analysis)
Placebo TabletNANot reportedNANAInsufficient OS events to estimate median and 95% confidence interval (Kaplan Meier analysis)

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Lower Limit
    0.3307
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95.03
    ci Upper Limit
    0.7299
    estimate Comment
    A hazard ratio \<1 favours AZD9291.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0004
    param Type
    Hazard Ratio (HR)
    param Value
    0.4913
    statistical Comment
    Determined using a log rank test stratified by stage, race and mutation type.
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Lower Limit
    0.3307
    ci Num Sides
    TWO_SIDED
    ci Pct Value
    95.03
    ci Upper Limit
    0.7299
    estimate Comment
    A hazard ratio \<1 favours AZD9291.
    group Ids
    1. OG000
    2. OG001
    non Inferiority Type
    SUPERIORITY
    p Value
    0.0004
    param Type
    Hazard Ratio (HR)
    param Value
    0.4913
    statistical Comment
    Determined using a log rank test stratified by stage, race and mutation type.
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. comment
        Insufficient OS events to estimate median and 95% confidence interval (Kaplan Meier analysis)
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
      2. comment
        Insufficient OS events to estimate median and 95% confidence interval (Kaplan Meier analysis)
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        NA
denoms
  1. counts
    1. group Id
      OG000
      value
      233
    2. group Id
      OG001
      value
      237
    units
    Participants
description
Defined as the time from the date of randomization until date of death due to any cause.
dispersion Type
95% Confidence Interval
groups
  1. description
    Taken once daily
    id
    OG000
    title
    AZD9291 80mg Tablet
  2. description
    Taken once daily
    id
    OG001
    title
    Placebo Tablet
param Type
MEDIAN
population Description
Full Analysis Set (FAS) stage IIA-IIIA patients
reporting Status
POSTED
time Frame
Up to approximately 7 years after the first patient is randomized (maximum follow up of 86 months)
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Months

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice